Nanjing Vazyme Biotech Co.,Ltd

Equities

688105

CNE100004ZK3

Pharmaceuticals

End-of-day quote Shanghai S.E. 18:00:00 2024-05-21 EDT 5-day change 1st Jan Change
24.24 CNY +0.33% Intraday chart for Nanjing Vazyme Biotech Co.,Ltd -4.60% -24.30%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Nanjing Vazyme Biotech Unit Gets Nod to Register Six Medical Devices; Shares Slump 14% MT
China stocks rise after new guidelines; HK shares drop RE
Nanjing Vazyme Biotech Swings to Loss in 2023 MT
Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Nanjing Vazyme Biotech Co.,Ltd announces an Equity Buyback for CNY 160 million worth of its shares. CI
Nanjing Vazyme Biotech Co., Ltd. authorizes a Buyback Plan. CI
Tranche Update on Nanjing Vazyme Biotech Co.,Ltd's Equity Buyback Plan announced on August 22, 2023. CI
Nanjing Vazyme Biotech Co.,Ltd's Equity Buyback announced on August 22, 2023, has closed with 618,077 shares, representing 0.15% for CNY 20.01 million. CI
Certain A Shares of Nanjing Vazyme Biotech Co., Ltd. are subject to a Lock-Up Agreement Ending on 15-NOV-2023. CI
Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Nanjing Vazyme Biotech Co.,Ltd(XSSC:688105) added to S&P Global BMI Index CI
Nanjing Vazyme Biotech Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Nanjing Vazyme Biotech Plans Up to 30 Million Yuan Share Buyback MT
Nanjing Vazyme Biotech Co.,Ltd announces an Equity Buyback for CNY 30 million worth of its shares. CI
Nanjing Vazyme Biotech Co., Ltd. authorizes a Buyback Plan. CI
Nanjing Vazyme Biotech Co., Ltd.(SHSE:688105) added to Shanghai Stock Exchange Health Care Sector Index CI
Vazyme Biotech Registers New Pneumonia Pathogen Detection Kit MT
Nanjing Vazyme Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nanjing Vazyme Biotech Unit Gets Registration Certificate for Pneumonia-Detecting Kit MT
Nanjing Vazyme Biotech Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Chart Nanjing Vazyme Biotech Co.,Ltd
More charts
Nanjing Vazyme Biotech Co Ltd is China-based company principally engaged in biopharmaceuticals. The Company's main business is the technology research and development and product development of functional proteins such as enzymes, antigens, antibodies, and polymer organic materials. The Company's products include polymerase chain reaction (PCR), reverse transcription, gene sequencing series and other biological reagent products, quantum dot immunofluorescence reagents, latex enhanced immune turbidity reagents and colloidal gold immunochromatography reagents and other point-of-care testing (POCT) Diagnostic reagents and instruments.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
24.24 CNY
Average target price
35.72 CNY
Spread / Average Target
+47.36%
Consensus
  1. Stock Market
  2. Equities
  3. 688105 Stock
  4. News Nanjing Vazyme Biotech Co.,Ltd
  5. Vazyme Biotech Registers New Pneumonia Pathogen Detection Kit